Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/karger/angiogenesis-in-lymphoproliferative-disorders-Hifooc6ieY
References (88)
-
T. Hideshima, D. Chauhan, Y. Shima, N. Raje, F. Davies, Y. Tai, S. Treon, B. Lin, R. Schlossman, P. Richardson, G. Muller, D. Stirling, K. Anderson (2000)
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.Blood, 96 9
-
M. Freeman, Francis Schneck, M. Gagnon, Christopher Corless, S. Soker, Kathy Niknejad, G. Peoples, M. Klagsbrun (1995)
Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis.Cancer research, 55 18
-
Á. Aguayo, E. Estey, H. Kantarjian, Taghi Mansouri, C. Gidel, M. Keating, F. Giles, Z. Estrov, B. Barlogie, M. Albitar (1999)
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.Blood, 94 11
-
A. Vacca, D. Ribatti, M. Iurlaro, Adriana Albini, M. Minischetti, Federico Bussolino, A. Pellegrino, R. Ria, M. Rusnati, Marco Presta, V. Vincenti, M. Persico, F. Dammacco (1998)
Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesisInternational Journal of Clinical and Laboratory Research, 28
-
J. Kandel, E. Bossy‐Wetzel, F. Radvanyi, M. Klagsbrun, J. Folkman, D. Hanahan (1991)
Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcomaCell, 66
-
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Studies on Treatment of Acute Promyelocytic Leukemia With Arsenic Trioxide: Remission Induction, Follow-Up, and Molecular Monitoring in 11 Newly Diagnosed and 47 Relapsed Acute Promyelocytic Leukemia Patients -
A. Bikfalvi, S. Klein, G. Pintucci, D. Rifkin (1997)
Biological roles of fibroblast growth factor-2.Endocrine reviews, 18 1
-
G. Roboz, S. Dias, G. Lam, W. Lane, S. Soignet, R. Warrell, S. Rafii (2000)
Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis.Blood, 96 4
-
F. Bertolini, L. Fusetti, P. Mancuso, A. Gobbi, C. Corsini, P. Ferrucci, Giovanni Martinelli, G. Pruneri (2000)
Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma.Blood, 96 1
-
D. Ribatti, A. Vacca, Beatrice Nico, F. Quondamatteo, Roberto Ria, M. Minischetti, Andrea Marzullo, Rainer Herken, L. Roncali, F. Dammacco (1999)
Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myelomaBritish Journal of Cancer, 79
-
M. Gaudry, O. Brégerie, V. Andrieu, J. Benna, M. Pocidalo, J. Hakim (1997)
Intracellular pool of vascular endothelial growth factor in human neutrophils.Blood, 90 10
-
H. Nguyen, J. Gabrilove, Daniel, Rifkin, Lynette Wilson (1993)
Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells.Blood, 81 3
-
T. Browder, C. Butterfield, B. Kräling, B. Shi, B. Marshall, M. O’Reilly, J. Folkman (2000)
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.Cancer research, 60 7
-
Kimberly Brandvold, P. Neiman, A. Ruddell (2000)
Angiogenesis is an early event in the generation of myc-induced lymphomasOncogene, 19
-
A. Perez-Atayde, S. Sallan, U. Tedrow, S. Connors, Elizabeth Allred, J. Folkman (1997)
Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia.The American journal of pathology, 150 3
-
Francesco Bertolini, Lisa Fusetti, C. Rabascio, S. Cinieri, Giovanni Martinelli, Giancarlo Pruneri (2000)
Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphomaLeukemia, 14
-
P. Salvén, A. Orpana, H. Joensuu (1999)
Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor.Clinical cancer research : an official journal of the American Association for Cancer Research, 5 3
-
Tanja Veikkola, M. Karkkainen, L. Claesson-Welsh, K. Alitalo (2000)
Regulation of angiogenesis via vascular endothelial growth factor receptors.Cancer research, 60 2
-
Xue Gu, A. Bikfalvi, Yuanzhong Chen, J. Caen, Z. Han (1995)
Constitutive and selective expression of basic fibroblast growth factor in human leukaemia cell linesEuropean Journal of Haematology, 55
-
W. Fiedler, U. Graeven, S. Ergün, S. Verago, N. Kilic, M. Stockschläder, D. Hossfeld (1997)
Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia.Blood, 89 6
-
S. Rajkumar, T. Leong, P. Roche, R. Fonseca, A. Dispenzieri, M. Lacy, J. Lust, T. Witzig, R. Kyle, M. Gertz, P. Greipp (2000)
Prognostic value of bone marrow angiogenesis in multiple myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 8
-
A. Griffioen, G. Molema (2000)
Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.Pharmacological reviews, 52 2
-
P. Salvén, Athina Lymboussaki, P. Heikkilä, Hilkka Jääskela-Saari, B. Enholm, K. Aase, G. Euler, U. Eriksson, K. Alitalo, H. Joensuu (1998)
Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors.The American journal of pathology, 153 1
-
Zhi-xiang Shen, Guo-Qiang Chen, J. Ni, Xiu-Shong Li, S. Xiong, Qian-Yao Qiu, Junxia Zhu, Wei Tang, Guan-lin Sun, Kan-Qi Yang, Y. Chen, Li Zhou, Zhi-Wen Fang, Yan-Ting Wang, Jun Ma, Peng Zhang, Ting-Dong Zhang, Saijuan Chen, Zhu Chen, Zhen-yi Wang (1997)
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.Blood, 89 9
-
M. Asano, A. Yukita, Tomoe Matsumoto, S. Kondo, Hideo Suzuki (1995)
Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121.Cancer research, 55 22
-
J. Folkman (1995)
Angiogenesis in cancer, vascular, rheumatoid and other diseaseNature Medicine, 1
-
N. Ferrara, K. Alitalo (1999)
Clinical applications of angiogenic growth factors and their inhibitorsNature Medicine, 5
-
P. Salvén, L. Teerenhovi, H. Joensuu (1999)
A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma.Blood, 94 10
-
(2001)
bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use -
T. Menzel, Z. Rahman, E. Calleja, Kenneth White, E. Wilson, R. Wieder, J. Gabrilove (1996)
Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine.Blood, 87 3
-
G. Yancopoulos, S. Davis, N. Gale, J. Rudge, S. Wiegand, J. Holash (2000)
Vascular-specific growth factors and blood vessel formationNature, 407
-
S. Dias, K. Hattori, Zhen-ping Zhu, B. Heissig, Margaret Choy, W. Lane, Yan Wu, A. Chadburn, E. Hyjek, Muhammad Gill, D. Hicklin, L. Witte, M. Moore, S. Rafii (2000)
Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration.The Journal of clinical investigation, 106 4
-
H. Foss, I. Araújo, G. Demel, Heike Klotzbach, M. Hummel, H. Stein (1997)
Expression of vascular endothelial growth factor in lymphomas and castleman's diseaseThe Journal of Pathology, 183
-
J. Wolf, W. Hubler (1975)
Tumour angiogenic factor associated with subcutaneous lymphomaBritish Journal of Dermatology, 92
-
J. Hu, H.-P. Sun, C. Niu, H. Yan, T. Yu, Guo-Qiang Chen, Z-X Shen, Sj Chen, Zhen-yi Wang, Zhu Chen (2001)
Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide -
A. Zomas, N. Anagnostopoulos, M. Dimopoulos (2000)
Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agentBone Marrow Transplantation, 25
-
Leo Schaerer, M. Schmid, B. Mueller, R. Dummer, G. Burg, W. Kempf (2000)
Angiogenesis in cutaneous lymphoproliferative disorders: microvessel density discriminates between cutaneous B-cell lymphomas and B-cell pseudolymphomas.The American Journal of dermatopathology, 22 2
-
P. Salvén, K. Anttonen, H. Repo, H. Joensuu, A. Orpana (2001)
Endotoxins induce and interferon‐α suppresses vascular endothelial growth factor (VEGF) production in human peripheral blood mononuclear cellsThe FASEB Journal, 15
-
Gerhard Gruber, J. Schwarzmeier, M. Shehata, M. Hilgarth, Rudolf Berger (1999)
Basic fibroblast growth factor is expressed by CD19/CD11c-positive cells in hairy cell leukemia.Blood, 94 3
-
H. Dvorak, L. Brown, M. Detmar, A. Dvorak (1995)
Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.The American journal of pathology, 146 5
-
L. Yao, S. Pike, J. Setsuda, Justin Parekh, G. Gupta, M. Raffeld, E. Jaffe, G. Tosato (2000)
Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12.Blood, 96 5
-
U. Wartiovaara, P. Salvén, H. Mikkola, R. Lassila, J. Kaukonen, V. Joukov, A. Orpana, A. Ristimäki, M. Heikinheimo, H. Joensuu, K. Alitalo, A. Palotie (1998)
Peripheral Blood Platelets Express VEGF-C and VEGF which Are Released during Platelet ActivationThrombosis and Haemostasis, 80
-
R. D'Amato, M. Loughnan, E. Flynn, J. Folkman (1994)
Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences of the United States of America, 91 9
-
D. Hanahan, J. Folkman (1996)
Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 86
-
A. Hori, R. Sasada, E. Matsutani, K. Naito, Y. Sakura, T. Fujita, Y. Kozai (1991)
Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor.Cancer research, 51 22
-
S. Pike, L. Yao, Karen Jones, B. Cherney, E. Appella, K. Sakaguchi, H. Nakhasi, J. Teruya-Feldstein, P. Wirth, G. Gupta, G. Tosato (1998)
Vasostatin, a Calreticulin Fragment, Inhibits Angiogenesis and Suppresses Tumor GrowthThe Journal of Experimental Medicine, 188
-
H. Agis, A. Weltermann, G. Mitterbauer, R. Thalhammer, M. Edelhäuser, H. Seewann, P. Valent, K. Lechner, C. Fonatsch, K. Geissler (1999)
Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemiaAnnals of Hematology, 78
-
M. Pepper, N. Ferrara, L. Orci, R. Montesano (1992)
Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro.Biochemical and biophysical research communications, 189 2
-
P. Salvén, P. Heikkilä, A. Anttonen, Mikael Kajanti, H. Joensuu (1997)
Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 10 11
-
R. Warren, Hui Yuan, M. Matli, N. Gillett, N. Ferrara (1995)
Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.The Journal of clinical investigation, 95 4
-
M. Allouche, F. Bayard, S. Clamens, G. Fillola, P. Sié, F. Amalric (1995)
Expression of basic fibroblast growth factor (bFGF) and FGF-receptors in human leukemic cells.Leukemia, 9 1
-
© 1999 Cancer Research Campaign Article no. bjoc.1998.0154 -
K. Kim, Bing Li, J. Winer, M. Armanini, N. Gillett, H. Phillips, N. Ferrara (1993)
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 362
-
G. Peoples, Srully Blotnick, Kazue Takahashi, Michael Freeman, Michael Klagsbrun, Timothy Eberlein (1995)
T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role.Proceedings of the National Academy of Sciences of the United States of America, 92 14
-
W. Bellamy, L. Richter, Y. Frutiger, T. Grogan (1999)
Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.Cancer research, 59 3
-
L. Holmgren, M. O’Reilly, J. Folkman (1995)
Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1
-
A. Vacca, D. Ribatti, L. Roncali, G. Ranieri, G. Serio, F. Silvestris, F. Dammacco (1994)
Bone marrow angiogenesis and progression in multiple myelomaBritish Journal of Haematology, 87
-
F. Goto, K. Goto, K. Weindel, J. Folkman (1993)
Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels.Laboratory investigation; a journal of technical methods and pathology, 69 5
-
P. Salvén, A. Orpana, L. Teerenhovi, H. Joensuu (2000)
Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients.Blood, 96 12
-
N. Ferrara, K. Carver-Moore, Helen Chen, M. Dowd, Lucy Lu, K. O'shea, L. Powell-Braxton, K. Hillan, M. Moore (1996)
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF geneNature, 380
-
R. Friesel, T. Maciag (1995)
Molecular mechanisms of angiogenesis: fibroblast growth factor signal transductionThe FASEB Journal, 9
-
Gunnar Juliusson, Fredrik Celsing, I. Turesson, S. Lenhoff, M. Adriansson, Claes Malm (2000)
Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma.British journal of haematology, 109 1
-
S. Singhal, J. Mehta, R. Desikan, D. Ayers, P. Roberson, Paul Eddlemon, N. Munshi, E. Anaissie, Carla Wilson, M. Dhodapkar, J. Zeldis, D. Siegel, J. Crowley, B. Barlogie (1999)
Antitumor activity of thalidomide in refractory multiple myeloma.The New England journal of medicine, 341 21
-
S. Rajkumar, Rafael Fonseca, A. Dispenzieri, M. Lacy, John Lust, T. Witzig, R. Kyle, M. Gertz, P. Greipp (2000)
Thalidomide in the treatment of relapsed multiple myeloma.Mayo Clinic proceedings, 75 9
-
N. Ferrara, T. Davis-Smyth (1997)
The biology of vascular endothelial growth factor.Endocrine reviews, 18 1
-
N. Ferrara, J. Winer, T. Burton, A. Rowland, M. Siegel, H. Phillips, T. Terrell, Gilbert Keller, A. Levinson (1993)
Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells.The Journal of clinical investigation, 91 1
-
Srully Blotnick, G. Peoples, Michael Freeman, Timothy Eberlein, Michael Klagsbrun (1994)
T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4+ and CD8+ T cells.Proceedings of the National Academy of Sciences of the United States of America, 91
-
Kneller, Raanani, Hardan, Avigdor, Levi, Berkowicz, Ben-Bassat (2000)
Therapy with thalidomide in refractory multiple myeloma patients — the revival of an old drugBritish Journal of Haematology, 108
-
R. Möhle, D. Green, M. Moore, R. Nachman, S. Rafii (1997)
Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets.Proceedings of the National Academy of Sciences of the United States of America, 94 2
-
S. Galimberti, F. Papineschi, A. Carmignani, R. Testi, R. Fazzi, M. Petrini (1999)
Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemiaBone Marrow Transplantation, 24
-
L. Liotta, J. Kleinerman, G. Saidel (1974)
Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation.Cancer research, 34 5
-
P. Carmeliet, Valérie Ferreira, G. Breier, S. Pollefeyt, L. Kieckens, M. Gertsenstein, M. Fahrig, A. Vandenhoeck, K. Harpal, Carmen Eberhardt, C. Declercq, J. Pawling, L. Moons, D. Collen, W. Risau, A. Nagy (1996)
Abnormal blood vessel development and lethality in embryos lacking a single VEGF alleleNature, 380
-
W. Risau (1995)
Differentiation of endotheliumThe FASEB Journal, 9
-
S. Schreiber, J. Ackermann, A. Obermair, H. Kaufmann, E. Urbauer, Katharina Aletaha, H. Gisslinger, A. Chott, H. Huber, J. Drach (2000)
Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularizationBritish Journal of Haematology, 110
-
Hua-tang Zhang, P. Craft, P. Scott, M. Ziche, H. Weich, A. Harris, R. Bicknell (1995)
Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells.Journal of the National Cancer Institute, 87 3
-
T. Padró, Sandra Ruiz, R. Bieker, H. Bürger, M. Steins, J. Kienast, T. Büchner, Wolfgang Berdel, R. Mesters (2000)
Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia.Blood, 95 8
-
S. Molica, G. Vitelli, D. Levato, G. Gandolfo, V. Liso (1999)
Increased serum levels of vascular endothelial growth factor predict risk of progression in early B‐cell chronic lymphocytic leukaemiaBritish Journal of Haematology, 107
-
(2000)
Atypical lymphoproliferative disorders; in Knowles DM (ed): Neoplastic Hematopathology -
G. Neufeld, T. Cohen, S. Gengrinovitch, Zoya Poltorak (1999)
Vascular endothelial growth factor (VEGF) and its receptorsThe FASEB Journal, 13
-
P. Salvén, L. Teerenhovi, H. Joensuu (1997)
A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma.Blood, 90 8
-
M. O’Reilly, L. Holmgren, Y. Shing, Catherine Chen, R. Rosenthal, M. Moses, William Lane, Yihai Cao, E. Sage, J. Folkman (1994)
Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinomaCell, 79
-
L. Reynolds, S. Killilea, D. Redmer (1992)
Angiogenesis in the female reproductive systemThe FASEB Journal, 6
-
L. Fusetti, G. Pruneri, A. Gobbi, C. Rabascio, N. Carboni, F. Peccatori, G. Martinelli, F. Bertolini (2000)
Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production.Cancer research, 60 9
-
G. Pruneri, F. Bertolini, D. Soligo, N. Carboni, A. Cortelezzi, P. Ferrucci, R. Buffa, G. Lambertenghi‐Deliliers, F. Pezzella (1999)
Angiogenesis in myelodysplastic syndromesBritish Journal of Cancer, 81
-
D. Ribatti, A. Vacca, B. Nico, M. Fanelli, L. Roncali, F. Dammacco (2009)
Angiogenesis spectrum in the stroma of B‐cell non‐Hodgkin's lymphomas. An immunohistochemical and ultrastructural studyEuropean Journal of Haematology, 56
-
B. Dankbar, T. Padró, R. Leo, B. Feldmann, M. Kropff, R. Mesters, H. Serve, Wolfgang Berdel, J. Kienast (2000)
Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.Blood, 95 8
-
E. Gunsilius, A. Petzer, G. Gastl (2000)
ANGIOGENIC GROWTH FACTORS AND ENDOSTATIN IN NON‐HODGKIN'S LYMPHOMABritish Journal of Haematology, 108
-
Harold Dvorak, T. Sioussat, L. Brown, B. Berse, J. Nagy, A. Sotrel, E. Manseau, L. Water, D. Senger (1991)
Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vesselsThe Journal of Experimental Medicine, 174
- Publisher
- Karger
- Copyright
- © 2001 S. Karger AG, Basel
- ISSN
- 0001-5792
- eISSN
- 1421-9662
- DOI
- 10.1159/000046615
- Publisher site
- See Article on Publisher Site
Abstract
In this review, the cellular and molecular mechanisms underlying angiogenesis in lymphoproliferative disorders are summarized, alongside with possible therapeutic applications. Although most of the initial studies in angiogenesis were done on solid tumors, recent data demonstrate the importance of angiogenesis in hematological malignancies including leukemia, lymphoma, and multiple myeloma. Expression of angiogenic polypeptides vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) correlate with clinical characteristics in leukemia and lymphoma, and their serum concentrations serve as predictors of poor prognosis. Antiangiogenic drugs, including thalidomide, arsenic trioxide, endostatin, vasostatin, and neutralizing antibodies to VEGF receptors, used alone or in combination with established chemo- or immunotherapy regimens, constitute a promising approach for the treatment of lymphoproliferative disorders.
Journal
Acta Haematologica – Karger
Published: Jan 1, 2001
Keywords: Multiple myeloma; Vascular endothelial growth factor; Angiogenesis; Fibroblast growth factor, basic; Leukemia; Lymphoma; Lymphoproliferative disorders; Malignancies, hematological